Exercise or conversion by Matthew Foehr of 33173 shares of OmniAb subject to Rule 16b-3
OABI Stock | USD 3.92 0.07 1.82% |
Under 62% of all OmniAb's traders are looking to take a long position. The analysis of the overall investor sentiment regarding OmniAb Inc suggests that some traders are interested. OmniAb's investing sentiment shows overall attitude of investors towards OmniAb Inc.
OmniAb |
Filed transaction by Omniab Inc director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
OmniAb's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the OmniAb's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
OmniAb Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards OmniAb can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
OmniAb Fundamental Analysis
We analyze OmniAb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OmniAb using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OmniAb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Operating Margin
Operating Margin Comparative Analysis
OmniAb is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
OmniAb Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with OmniAb stock to make a market-neutral strategy. Peer analysis of OmniAb could also be used in its relative valuation, which is a method of valuing OmniAb by comparing valuation metrics with similar companies.
Peers
OmniAb Related Equities
BCAB | Bioatla | 12.95 | ||||
OLMA | Olema Pharmaceuticals | 11.56 | ||||
KROS | Keros Therapeutics | 3.86 | ||||
ERAS | Erasca | 3.85 | ||||
LEGN | Legend Biotech | 2.99 | ||||
CGEM | Cullinan Oncology | 2.62 | ||||
PMVP | Pmv Pharmaceuticals | 2.55 | ||||
VRNA | Verona Pharma | 2.51 | ||||
ITOS | Iteos Therapeutics | 2.34 | ||||
GLUE | Monte Rosa | 1.68 | ||||
IDYA | Ideaya Biosciences | 0.71 | ||||
EWTX | Edgewise Therapeutics | 0.69 | ||||
ACET | Adicet Bio | 1.10 | ||||
IKNA | Ikena Oncology | 1.16 | ||||
VOR | Vor Biopharma | 1.25 | ||||
IPSC | Century Therapeutics | 2.42 | ||||
PASG | Passage Bio | 5.56 |
Complementary Tools for OmniAb Stock analysis
When running OmniAb's price analysis, check to measure OmniAb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OmniAb is operating at the current time. Most of OmniAb's value examination focuses on studying past and present price action to predict the probability of OmniAb's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OmniAb's price. Additionally, you may evaluate how the addition of OmniAb to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |